258 related articles for article (PubMed ID: 32921169)
1. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery.
Shringarpure M; Gharat S; Momin M; Omri A
Expert Opin Drug Deliv; 2021 Feb; 18(2):169-185. PubMed ID: 32921169
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A Novel Approach to Diagnosis and Treatment.
Khan J; Yadav S
Pharm Nanotechnol; 2023 Oct; ():. PubMed ID: 37818558
[TBL] [Abstract][Full Text] [Related]
3. A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery.
Singh R; Brumlik C; Vaidya M; Choudhury A
Recent Pat Nanotechnol; 2020; 14(3):174-192. PubMed ID: 32384043
[TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain delivery of antipsychotics using nanotechnology: a review.
Tan MSA; Parekh HS; Pandey P; Siskind DJ; Falconer JR
Expert Opin Drug Deliv; 2020 Jun; 17(6):839-853. PubMed ID: 32343186
[TBL] [Abstract][Full Text] [Related]
5. Strategies to facilitate or block nose-to-brain drug delivery.
Martins PP; Smyth HDC; Cui Z
Int J Pharm; 2019 Oct; 570():118635. PubMed ID: 31445062
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?
Rehman S; Nabi B; Zafar A; Baboota S; Ali J
Expert Opin Drug Deliv; 2019 Dec; 16(12):1355-1366. PubMed ID: 31663382
[No Abstract] [Full Text] [Related]
7. Drug delivery systems from nose to brain.
Misra A; Kher G
Curr Pharm Biotechnol; 2012 Sep; 13(12):2355-79. PubMed ID: 23016642
[TBL] [Abstract][Full Text] [Related]
8. Nasal-nanotechnology: revolution for efficient therapeutics delivery.
Kumar A; Pandey AN; Jain SK
Drug Deliv; 2016; 23(3):681-93. PubMed ID: 24901207
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical and physiological considerations for efficient nose-to-brain targeting.
Bahadur S; Pathak K
Expert Opin Drug Deliv; 2012 Jan; 9(1):19-31. PubMed ID: 22171740
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
Islam SU; Shehzad A; Ahmed MB; Lee YS
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
[TBL] [Abstract][Full Text] [Related]
11. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.
Pardeshi CV; Belgamwar VS
Expert Opin Drug Deliv; 2013 Jul; 10(7):957-72. PubMed ID: 23586809
[TBL] [Abstract][Full Text] [Related]
12. Nasal formulations for drug administration and characterization of nasal preparations in drug delivery.
Scherließ R
Ther Deliv; 2020 Mar; 11(3):183-191. PubMed ID: 32046624
[TBL] [Abstract][Full Text] [Related]
13. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
15. Recent patents review on intranasal administration for CNS drug delivery.
Jogani V; Jinturkar K; Vyas T; Misra A
Recent Pat Drug Deliv Formul; 2008; 2(1):25-40. PubMed ID: 19075895
[TBL] [Abstract][Full Text] [Related]
16. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnological advances in the treatment of epilepsy: a comprehensive review.
Rai G; Sharma S; Bhasin J; Aggarwal K; Ahuja A; Dang S
Nanotechnology; 2024 Jan; 35(15):. PubMed ID: 38194705
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles for direct nose-to-brain delivery of drugs.
Mistry A; Stolnik S; Illum L
Int J Pharm; 2009 Sep; 379(1):146-57. PubMed ID: 19555750
[TBL] [Abstract][Full Text] [Related]
19. Intranasal drug delivery: opportunities and toxicologic challenges during drug development.
Keller LA; Merkel O; Popp A
Drug Deliv Transl Res; 2022 Apr; 12(4):735-757. PubMed ID: 33491126
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
